12217-full
Singer
Sex: F
Data Quality: 0 stars
MS: 10 yrs
Type: Relapsing-Remitting
Sensation: Moderate
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: moderate
Swallowing: moderate
Upper limb: moderate
Walking: moderate
Singer
Female, 55 years
Oklahoma City, OK
Primary Condition
MS and 1 more ▼
Type
Relapsing-Remitting
First symptom
Diagnosis
See more

Treatment charts require Flash. If you have problems installing Flash, visit the FAQ for help.

Get Adobe Flash player

Singer's FTY720 (Fingolimod) Clinical Trial is for:

  • Other

Singer's side effects of FTY720 (Fingolimod) Clinical Trial:

Singer's FTY720 (Fingolimod) Clinical Trial History (Stopped)
1 mg Daily Apr 08, 2003 - Apr 09, 2008
1 mg Daily Apr 09, 2008 - Jun 01, 2009
Stopped Other Jun 01, 2009
Evaluations
Date Dosage Other Perceived effectiveness Side Effects Adherence Burden
Jun 01, 2009 1 mg Daily Led_efficacy_1Led_defaultLed_defaultLed_default ModerateModerateModerateModerate AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all

About FTY720 (Fingolimod) Clinical Trial (Other)

FTY720 is the name used during clinical trials for the drug fingolimod. On September 22, 2010, fingolimod became the first oral disease modifying drug approved by the FDA as Gilenya to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis.

Learn more about FTY720 (Fingolimod) Clinical Trial in our FTY720 (Fingolimod) Clinical Trial Community Report.

Back to Singer's Profile